🇺🇸 Piperacillin-tazobactam in United States

FDA authorised Piperacillin-tazobactam on 16 February 2021 · 3,679 US adverse-event reports

Marketing authorisation

FDA — authorised 16 February 2021

  • Application: ANDA208675
  • Marketing authorisation holder: SAGENT PHARMS INC
  • Status: supplemented

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 650 reports (17.67%)
  2. Off Label Use — 515 reports (14%)
  3. Acute Kidney Injury — 513 reports (13.94%)
  4. Pyrexia — 451 reports (12.26%)
  5. Drug Interaction — 304 reports (8.26%)
  6. Condition Aggravated — 253 reports (6.88%)
  7. Drug Reaction With Eosinophilia And Systemic Symptoms — 251 reports (6.82%)
  8. Thrombocytopenia — 250 reports (6.8%)
  9. Septic Shock — 248 reports (6.74%)
  10. Rash — 244 reports (6.63%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Piperacillin-tazobactam approved in United States?

Yes. FDA authorised it on 16 February 2021.

Who is the marketing authorisation holder for Piperacillin-tazobactam in United States?

SAGENT PHARMS INC holds the US marketing authorisation.